Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYN023 vs HRIG with rabies vaccine in category III rabies exposure
CTR20201819Phase 3Completed
- Sponsor
- Longrui Pharmaceutical
- Start
- Sep 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of zamerovimab + mazorelvimab in rabies, sponsored by Longrui Pharmaceutical. Started Sep 2020; status: completed.
02
Drugs
zamerovimab + mazorelvimab
03
Conditions
rabies
Beyond the preview
Go deeper on CTR20201819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201819.